Yahoo
NYSE - Delayed Quote USD

Penumbra, Inc. (PEN)

318.31 -5.73 (-1.77%)
At close: October 28 at 4:00:02 PM EDT
321.91 +3.60 (+1.13%)
Pre-Market: 5:50:40 AM EDT
Trade PEN on Coinbase
Chart Range Bar
Loading chart for PEN
  • Previous Close 324.04
  • Open 321.04
  • Bid --
  • Ask 335.00 x 12000
  • Day's Range 316.35 - 321.15
  • 52 Week Range 221.26 - 362.41
  • Volume 851,285
  • Avg. Volume 338,350
  • Market Cap (intraday) 12.538B
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) 78.21
  • EPS (TTM) 4.07
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 362.54
  • Morningstar Rating Rating available with Stock Picks access

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

www.penumbrainc.com

4,700

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PEN
2.38%
S&P 500 (^GSPC)
13.13%

1-Year Return

PEN
35.16%
S&P 500 (^GSPC)
12.38%

3-Year Return

PEN
65.09%
S&P 500 (^GSPC)
88.08%

5-Year Return

PEN
14.54%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 390.05M
Earnings 34.81M
Profit Margin 8.92%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100M
200M
300M
9.0%
10.0%
11.0%
12.0%

Analyst Insights

View More

Analyst Price Targets

320.00
362.54 Average
318.31 Current
374.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/6/2026
Analyst Evercore ISI Group
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 335 -> 320

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.67%

  • Return on Assets (ttm)

    6.42%

  • Return on Equity (ttm)

    11.37%

  • Revenue (ttm)

    1.5B

  • Net Income Avi to Common (ttm)

    160.59M

  • Diluted EPS (ttm)

    4.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    658.8M

  • Total Debt/Equity (mrq)

    13.90%

  • Levered Free Cash Flow (ttm)

    161.1M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: